Indianapolis, IN, United States of America

Richard Waltz Harper

This inventor holds 30 USPTO granted patents, primarily in Antithrombotic Agents. Top assignees: Eli Lilly and Company, Other. Active years: 1977-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Waltz Harper. Retrieved from https://idiyas.com/inventor/richard-waltz-harper

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30

% Patents Active = 86.7

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 244(Granted Patents)

Location History:

Whitehall, MI (US) (2004)
Indianapolis, IN (US) (1977 - 2005)
Fort Worth, TX (US) (2007)
New Braunfels, TX (US) (2018 - 2019)

Company Filing History:

26 out of 4,514

Eli Lilly and Company

patents

3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1977-2019

Loading Chart...

Areas of Expertise:

Antithrombotic Agents

sPLA2 Inhibitors

Gaseous Emissions

Variable Output Gear

Hydroxyfunctional Amides

Thrombin Inhibitors

Chromogenic Compounds

Roof Ventilation

Substituted Carbazoles

Anti-Tumor Compounds

Substituted Thiadiazolotriazinediones

Phenyl Acetamides

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10176696 - Apparatus and process for measuring gaseous emissions from an engine (2019-01-08),

2. 10054204 - Variable output planetary gear set with electromagnetic braking (2018-08-21),

3. D556982 - Shoe sole (2007-12-11),

4. 6939890 - sPLA2 inhibitors (2005-09-06),

5. 6933313 - Substituted carbazoles as inhibitors of sPLA2 (2005-08-23),

6. 6831095 - Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors (2004-12-14),

7. 6780099 - Roof ventilation system (2004-08-24),

8. 6713645 - Substituted tricyclics (2004-03-30),

9. 6541499 - Antithrombotic agents (2003-04-01),

10. 6448422 - Chromogenic compound (2002-09-10),

11. 6391908 - Oxime amide indole type sPLA2 inhibitors (2002-05-21),

12. 6391901 - Thrombin inhibitors (2002-05-21),

13. 6359136 - Antithrombotic agents (2002-03-19),

14. 6353128 - Phenyl acetamides as sPLA2 inhibitors (2002-03-05),

15. 6350774 - Antithrombotic agents (2002-02-26),

Title: Richard Waltz Harper: Innovator in sPLA2 Inhibitors

Introduction: Richard Waltz Harper, based in Indianapolis, Indiana, is a prolific inventor with an impressive record of 26 patents. His work primarily focuses on developing innovative compounds aimed at addressing inflammatory diseases, showcasing his commitment to advancing medical science.

Latest Patents: Among Harper's notable patents are his latest innovations related to sPLA2 inhibitors. One such patent discloses a class of novel indole compounds that can inhibit the sPLA-mediated release of fatty acids, providing potential treatment options for conditions like septic shock. Another patent emphasizes substituted carbazoles with a specific formula (I) that also serve as inhibitors of sPLA2, detailing their utility in treating inflammatory conditions by targeting the same biochemical pathways.

Career Highlights: Richard Harper is a key contributor at Eli Lilly and Company, a leading pharmaceutical company known for its extensive research and development efforts in innovative healthcare solutions. His work is instrumental in fostering new therapeutic avenues and enhancing patient care through scientific breakthroughs.

Collaborations: In his innovative journey, Harper collaborates with esteemed colleagues such as Ho-Shen Lin and Daniel Jon Sall. Their collective expertise strengthens the research efforts at Eli Lilly, driving forward the discovery of impactful pharmaceutical interventions.

Conclusion: Richard Waltz Harper stands as a notable figure in the realm of pharmaceutical innovation, with a focus on developing sPLA2 inhibitors that hold promise for treating severe inflammatory diseases. Through his contributions at Eli Lilly and his collaborations with talented coworkers, Harper continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]